The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients

This is an investigator-initiated study partially subsidized by the Unilab- Biomedis- Biomedis by providing the drug Renogen® 4,000 units/vial, H2 Receptor Blocker and Ferrous Sulfate. The supporting company will also pay the monthly laboratory and ultrasound of the brachial artery of the patients. All patients for inclusion will sign an informed consent. The study will be conducted for 3 months. Patients will be required to follow-up at least twice a month for 3 months to give the 2 week supply of erythropoietin alpha (Renogen), administration of subcutaneous drug, give the laboratory request , for physical examination and to return the pre filled syringe to monitor their compliance. The patients will be given free Renogen, H2 Blockers and ferrous sulfate, free monthly CBC test and ultrasound of the brachial artery on baseline and after the 3rd month of the administration of the drug. No monetary compensation will be given to the patient.

The following data will be collected: patient age, sex, primary renal disease, and weight. The following laboratory data will be collected at baseline: complete blood count, reticulocyte count, blood urea nitrogen, serum creatinine, lipid profile, albumin, calcium, phosphorus, ALT, serum ferritin, TIBC, reticulocyte count, CRP and albumin and ultrasound of the brachial artery to assess the flow mediated dilatation. The following laboratory test will be repeated on the 1st and 3rd month. CBC will be repeated monthly. Reticulocyte count, TIBC and serum ferritin will be repeated after 1 month of using Renogen. Serum ferritin needs to be >200 and TSAT ng/ml prior to entry into the study. The patient will have a folder for medical record keeping. Only the investigators can access the patients' medical record and all subsequent recording of data will be anonymized. The investigators may generate or derive in the course of performing the Study (''Confidential Information''), to use such confidential information only for the purpose of the study, and not to transfer or disclose confidential information to any third party other than study personnel involved in the performance of the study with ''need to know''.

Vascular Assessment

Endothelium-dependent flow-mediated vasodilatation and endothelium-independent vasodilatation (NMD) of the brachial artery will be assessed non-invasively, using high-resolution ultrasound based on the International Brachial Artery Reactivity Task Force. Measurements will be performed using a single observer using an ATL 5000 ultrasound system (Advanced Technology Laboratories Inc., Bothell, WA, USA) with a 12-MHz prob. All vasoactive medications will be withheld for 24h before the procedure. The subjects will remain at rest in the supine position for at least 15min before the examination starts. Subject's arm will be comfortably immobilized in the extended position to allow consistent recording of the brachial artery 2-4cm above the antecubital fossa. Three adjacent measurements of end-diastolic brachial artery diameter will be performed from single two-dimensional frames. All ultrasound images will be recorded on an S-VHS videotape for subsequent blinded analysis. A pneumatic tourniquet will be inflated to 300mmHg with obliteration of the radial pulse. After 5min, the cuff will be deflated. Flow measurements will be performed 60s after deflation. After a further 15min, measurements will be repeated, and after 3 minutes of administration of sublingual glyceryl trinitrate (400mcg). Nitroglycerine will be given to determine the maximum obtainable vasodilator response, and to serve as a measure of endothelium-independent vasodilation reflecting vascular smooth muscle function. NTG should not be administered to individuals with clinically significant bradycardia or hypotension. The maximum FMD diameters will be calculated as the average of the three consecutive maximum diameter measurements after hyperemia and nitroglycerin, respectively. The FMD will then calculated as the percent change in diameter compared with baseline resting diameters.

Patients will be censored at death, modality change (PD to HD or to kidney transplantation), or at the end of the follow-up period. Patients who will not complete the three months study period and the reasons for their withdrawal will be described.

The outcome measures for efficacy will be defined as the correction of anemia to a hematocrit (Hct) of 33-36% or hemoglobin (Hb) of 10- 11 g/L. The total dose of Renogen® required per patient to maintain the target Hb/Hct and the time required to reach the target will be determined.

Patients will be started on Renogen® at 150 units/kg/week. Oral iron supplements will be started at 105 mg elemental iron per day. It will be provided by Unilab- Biomedis. If the patients will not have an increase in Hb by 1-2 g/dl or an increase in the reticulocyte count after the first month of treatment, a test for fecalysis with occult blood (FOB) will be done. If the result will be negative, the dose of Renogen® will be increased to 200 units/kg/week. If FOB will be positive, H2 Blocker will be prescribed and the same dose of Renogen® continued. If on the second month of treatment there will still be no increase in the Hb or reticulocyte count, FOB will be performed again following the algorithm mentioned above. If FOB will still test positive however, the patient will be dropped from the study. Patients who have severe adverse reaction such as anaphylactic shock and difficulty of breathing to Epoeitin Alpha Renogen will also be dropped out. All drop-out patients will be followed up by the investigators and all their hospital expenses will be paid by Unilab- Biomedis if needed. H2 Blocker will be provided by Unilab- Biomedis. 10% of the population might need H2 blocker and oral Iron therapy. These will be provided by Unilab- Biomedis.

If the Hb/Hct will increase beyond the target, the Renogen® dose will be reduced by 50 units/kg/week. If the Hb/Hct will be below target, the Renogen® dose will be increased by 50 units/kg/week.

For any adverse events noted with the use of Renogen® such as arterial hypertension, cerebral convulsion/hypertensive encephalopathy and thrombo-embolism will be reported to Adverse Event Committee of NKTI. All adverse events will be described. Hospital expenses will be shouldered by Unilab- Biomedis.

Statistical Analysis

This is a pilot study on Renogen®, hence no sample size calculation is needed. Due to limited budget, the investigators will only recruit 30 new PD patients as minimum number to make a significant result. The investigators will use frequency and percentages to summarize categorical variables. To determine the efficacy of the drug, Wilcoxon Signed Ranks Test will be used. Spearman Coefficient of Correlation will also be used. Five percent level of significance will be assumed.

Conflict of Interest

This study will intend to gather sufficient evidence for real drug effect and statistical power for a full-scale study. A long- term may be recommended after the pilot study.

The Investigators have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Publishing Right and Ownership of Result

The Investigators own the rights in and to any inventions, discoveries, improvements related to or derived from, either directly or indirectly, the study which are conceived of or reduced to practice or developed by Investigators as a result of the study. The investigators have the right to publish the study results as well. The Unilab- Biomedis will be informed if the study is for publication. The investigators may ask for financial assistance for the publication like the publication fee.

Specimen Handling

The investigators will store, use and dispose any Renogen, Ferrous Sulfate and H2 Receptor Blocker, and will ensure that the Renogen, Ferrous Sulfate and H2 Receptor Blocker are used solely for the conduct of the study. The investigators will maintain appropriate controls to ensure proper handling of any such drugs. Upon completion of the study, the investigators will return the unused Renogen, Ferrous Sulfate and H2 Receptor Blocker to Unilab- Biomedis.